| 阿德福韦酯联合恩替卡韦治疗对拉米夫定耐药的慢性乙型肝炎临床疗效观察 |
| |
| 引用本文： | 胡长征.阿德福韦酯联合恩替卡韦治疗对拉米夫定耐药的慢性乙型肝炎临床疗效观察[J].中国医药指南,2011,9(16):178-179. |
| |
| 作者姓名： | 胡长征 |
| |
| 作者单位： | 广东省江门市中心医院感染科,广东,江门,529030 |
| |
| 摘 要： | 目的比较阿德福韦酯联合拉米夫定和阿德福韦酯联合恩替卡韦对拉米夫定耐药的慢性乙型肝炎患者的疗效。方法 140例对拉米夫定耐药慢性乙型肝炎的门诊患者随机分为两组:联合用药A组和联合用药B组。A组患者服用阿德福韦酯10mg/d,加服拉米夫定100mg/d,B组在服用阿德福韦酯时,服恩替卡韦0.5mg/d,所有患者均治疗2年。治疗前、治疗0.5、1、1.5和2年分别检测HBV-DNA和ALT。结果两组患者治疗后平均ALT水平均显著降低,HBV-DNA转阴率和ALT复常率显著增加,而联合用药B组明显优于A组。结论对于拉米夫定耐药的慢性乙型肝炎患者,可优先考虑采用阿德福韦酯联合恩替卡韦进行治疗。
|
| 关 键 词： | 阿德福韦酯 恩替卡韦 拉米夫定耐药 慢性乙型肝炎患者 |
The Clinical Curative Effects Adefovir Dipivoxil and Entecavir combined in Lamivudine Resistance of Chronic Hepatitis B Patients |
| |
| HU Chang-zheng.The Clinical Curative Effects Adefovir Dipivoxil and Entecavir combined in Lamivudine Resistance of Chronic Hepatitis B Patients[J].Guide of China Medicine,2011,9(16):178-179. |
| |
| Authors: | HU Chang-zheng |
| |
| Institution: | HU Chang-zheng(Department of Infectious Diseases,Jiangmen Central Hospital,Jiangmen 529030) |
| |
| Abstract: | Objective Compare curative effect on adefovir dipivoxil and lamivudine combined or adefovir dipivoxil and entecavir combined in lamivudine resistance of chronic hepatitis B patients.Methods 140 lamivudine resistance of chronic hepatitis B patients were randomly divided into two groups: A group and B group.A groups of patients take adefovir dipivoxil 10mg/d and lamivudine 100mg/d;B group take adefovir dipivoxil 10mg/d and entecavir 0.5 mg/d,all patients were treated for 2 years.In before treatment and in 0.5... |
| |
| Keywords: | Adefovir dipivoxil Entecavir Lamivudine resistance Chronic hepatitis B |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
